Synapse: Law for Life Sciences

 

 

 

 

Welcome to Synapse - connecting you with news and analysis on legal and commercial issues in the life sciences.

Webinars
visit N-Site
visit the Taylor Wessing Patent Map
visit Global Data Hub

Licensing out - try not to get benched

 

When licensing out a product to a bigger player, one of the risks is that the licensed product is shelved and the licensor never sees any revenue from it. As Colin McCall and Justyna Ostrowska explain, this can happen for many reasons, and the licence agreement should anticipate that.

 

arrowView our previous articles

Topical Issues

 

UK increases scrutiny of tech and life sciences deals - The UK remains an attractive environment for foreign investments. However, as Paolo Palmigiano explains, in recent months, we've seen trends that indicate that mergers and acquisitions in the tech and life sciences sectors may be subject to closer scrutiny by the UK competition authority and by the UK government in future....read more

 

US buys up entire stock of remdesivir - After the US was reported to have bought the entire stock of remdesivir from producer Gilead, Judith Krens asks whether there are ways to intervene in the Netherlands (and in other European countries)....
read more

 

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents - Adrian Toutoungi, Matthew Royle and Paul England discuss whether this case has shifted the boundaries of patent protection, or merely clarified the status quo....read more

 

Private equity investment in life sciences sector - Our experts explore some of the potential benefits and challenges for life sciences companies considering private equity investment from the perspective of investee companies, as well as the emerging trends we've identified around the nature of PE investments into the sector....read more

 

Patent diary – July 2020: Court refuses to strike out Chiesi's quia timet injunction claim - Paul England reports on the Patent Court's refusal to strike out a quia timet injunction claimed by Chiesi against Teva....read more

Subscribe to Synapse

Receive our monthly newsletter keeping you updated on recent developments and events in the Life Sciences sector.
Register here